Oncology and Hematology

Episodes 65-80 of 117

• 

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  MinuteCE®

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer   

  RestartResume

  Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer   

  MinuteCE®

  Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer   

  0.75 program credits

  • 

    

    Tanya Dorff, MD

  0.75 program credits

• 

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  MinuteCE®

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  0.75 program credits

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  MinuteCE®

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  MinuteCE®

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  RestartResume

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  MinuteCE®

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  MinuteCE®

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer

  1.00 credit 10 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 credit 10 episodes

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  MinuteCE®

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  MinuteCE®

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  MinuteCE®

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management

  RestartResume

  Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management

  CME/CE

  Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management

  0.25 credits

  • 

    

    Caroline Piatek, MD

  • 

    

    Irina Murakhovskaya, MD

  0.25 credits

• 

  RestartResume

  Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability   

  RestartResume

  Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability   

  MinuteCE®

  Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability   

  1.25 program credits

  • 

    

    Thomas Kipps, MD, PhD

  • 

    

    William Wierda, MD, PhD

  1.25 program credits

• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• Next